Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO ...

Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...

Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...

Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

At an investor summit in New York on Tuesday, activist investor Starboard called out Pfizer's PFE board of directors to take ...

Pfizer (PFE) faces renewed calls for change as Jeffrey Smith, CEO of Starboard Value makes his case for his activist stance ...

Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

Activist investor Starboard Value urged Pfizer’s (PFE) leadership to do “something different” and hold management accountable ...

Activist hedge fund Starboard Value believes the root cause of Pfizer’s issues are the low expected returns on its research and development investments, including investments done both internally and ...